Imago BioSciences

Contact us to add description: recruit@workinbiotech.com

Contact us to add description: recruit@workinbiotech.com

Imago Biosciences is developing treatments for patients with life-threatening diseases of the bone marrow. Lysine-specific demethylase 1 (LSD1) is a protein that plays a key role in the behavior of malignant blood cells by influencing which genes are expressed. Imago focuses on studying the activity of LSD1, which they believe offers the greatest chance of treating bone marrow diseases since LSD1 plays a unique role in each step of blood cell formation. This includes the discovery and development of identifying small molecule inhibitors and degraders of LSD1. Imago’s lead product, bomedemstat, is an orally available inhibitor of LSD1 that is currently being tested in clinical trials for patients with myeloproliferative neoplasms. Imago BioSciences is a clinical-stage biopharmaceutical company developing novel small molecule product candidates that target lysine-specific demethylase 1, or LSD1, an enzyme that plays a central role in the production of blood cells in the bone marrow. The company's lead product candidate, bomedemstat, is an orally available, small molecule inhibitor of LSD1. Bomedemstat is currently in clinical trials for the treatment of essential thrombocythemia (ET) and myelofibrosis (MF). On November 21, 2022, Merck acquired Imago BioSciences for $1.35 billion.

Jobs: